Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Teva
Healthtrust
Merck
Daiichi Sankyo
Queensland Health
Julphar
Accenture
Boehringer Ingelheim

Generated: June 20, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PENTOXIFYLLINE

« Back to Dashboard

Clinical Trials for PENTOXIFYLLINE

Trial ID Title Status Sponsor Phase Summary
NCT00000579 Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.
NCT00000646 Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS Completed Hoechst Marion Roussel Phase 1 To determine whether pentoxifylline lowers tumor necrosis factor (TNF) levels in AIDS patients. Pentoxifylline decreases tumor necrosis factor (TNF), and therefore should decrease such TNF-intensified events as cachexia, enhanced HIV expression, and inhibition of zidovudine (AZT) activity.
NCT00000646 Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 To determine whether pentoxifylline lowers tumor necrosis factor (TNF) levels in AIDS patients. Pentoxifylline decreases tumor necrosis factor (TNF), and therefore should decrease such TNF-intensified events as cachexia, enhanced HIV expression, and inhibition of zidovudine (AZT) activity.
NCT00001437 Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis Completed National Cancer Institute (NCI) Phase 2 After initial assessment of their condition by specified clinical and laboratory parameters, each of the patients will be treated for 8 weeks at the standard pentoxifylline dose (400 mg po TID). Objective and subjective response parameters will be re-assessed at the end of the treatment and 8 weeks later for possible decay of response.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for PENTOXIFYLLINE

Condition Name

Condition Name for PENTOXIFYLLINE
Intervention Trials
Alcoholic Hepatitis 6
Cardiovascular Diseases 3
HIV Infections 3
Nonalcoholic Steatohepatitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for PENTOXIFYLLINE
Intervention Trials
Hepatitis A 9
Hepatitis 9
Hepatitis, Alcoholic 9
Kidney Diseases 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for PENTOXIFYLLINE

Trials by Country

Trials by Country for PENTOXIFYLLINE
Location Trials
United States 67
Taiwan 5
Canada 4
Iran, Islamic Republic of 4
France 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for PENTOXIFYLLINE
Location Trials
Texas 6
Ohio 5
Minnesota 5
California 4
Missouri 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for PENTOXIFYLLINE

Clinical Trial Phase

Clinical Trial Phase for PENTOXIFYLLINE
Clinical Trial Phase Trials
Phase 4 14
Phase 3 17
Phase 2/Phase 3 7
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for PENTOXIFYLLINE
Clinical Trial Phase Trials
Completed 38
Recruiting 14
Unknown status 14
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for PENTOXIFYLLINE

Sponsor Name

Sponsor Name for PENTOXIFYLLINE
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 5
National Taiwan University Hospital 5
Indiana University 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for PENTOXIFYLLINE
Sponsor Trials
Other 116
NIH 14
Industry 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Argus Health
Cantor Fitzgerald
AstraZeneca
McKesson
Citi
Accenture
Federal Trade Commission
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.